CD22 and leukemia: Using a range of effector (CD22 CAR-T) to target (leukemia line) ratios (E:T) we found that the co-incubation of CAR-T with leukemia cell lines induces a profound decrease in the number of cell surface antigens expressed on the cell surface (Figure 3).